Related Experiment Video
Updated: Jan 19, 2026
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization
Allison B Powell1, Sridevi Yadavilli2, Devin Saunders3
1George Washington University Cancer Center, George Washington University, Washington, DC, USA.
Background:
Medulloblastoma (MB), the most common pediatric brain cancer, presents with a poor prognosis in a subset of patients with high risk disease, or at recurrence, where current therapies are ineffective. Cord blood (CB) natural killer (NK) cells may be promising off-the-shelf effector cells for immunotherapy due to their recognition of malignant cells without the need for a known target, ready availability from multiple banks, and their potential to expand exponentially. However, they are currently limited by immune suppressive cytokines secreted in the MB tumor microenvironment including Transforming Growth Factor β (TGF-β). Here, we address this challenge in in vitro models of MB.
Methods:
CB-derived NK cells were modified to express a dominant negative TGF-β receptor II (DNRII) using retroviral transduction. The ability of transduced CB cells to maintain function in the presence of medulloblastoma-conditioned media was then assessed.
Results:
We observed that the cytotoxic ability of nontransduced CB-NK cells was reduced in the presence of TGF-β-rich, medulloblastoma-conditioned media (21.21 ± 1.19% killing at E:T 5:1 in the absence vs. 14.98 ± 2.11% in the presence of medulloblastoma-conditioned media, n = 8, p = 0.02), but was unaffected in CB-derived DNRII-transduced NK cells (21.11 ± 1.84% killing at E:T 5:1 in the absence vs. 21.81 ± 3.37 in the presence of medulloblastoma-conditioned media, n = 8, p = 0.85. We also observed decreased expression of CCR2 in untransduced NK cells (mean CCR2 MFI 826 ± 117 in untransduced NK + MB supernatant from mean CCR2 MFI 1639.29 ± 215 in no MB supernatant, n = 7, p = 0.0156), but not in the transduced cells. Finally, we observed that CB-derived DNRII-transduced NK cells may protect surrounding immune cells by providing a cytokine sink for TGF-β (decreased TGF-β levels of 610 ± 265 pg/mL in CB-derived DNRII-transduced NK cells vs. 1817 ± 342 pg/mL in untransduced cells; p = 0.008).
Conclusions:
CB NK cells expressing a TGF-β DNRII may have a functional advantage over unmodified NK cells in the presence of TGF-β-rich MB, warranting further investigation on its potential applications for patients with medulloblastoma.
Insights
Modified cord blood natural killer (NK) cells resist immune suppression from medulloblastoma tumors. These engineered NK cells show promise for treating pediatric brain cancer by overcoming tumor microenvironment challenges.
Area of Science:
- Immunotherapy
- Oncology
- Cell Biology
Background:
- Medulloblastoma (MB) is a common pediatric brain cancer with poor prognosis in high-risk or recurrent cases.
- Cord blood (CB) natural killer (NK) cells are potential off-the-shelf immunotherapy agents but are hindered by the MB tumor microenvironment, particularly Transforming Growth Factor β (TGF-β).
Purpose of the Study:
- To investigate the efficacy of genetically modified CB NK cells in overcoming TGF-β-mediated immune suppression in medulloblastoma models.
- To assess the functional advantage of NK cells engineered to express a dominant-negative TGF-β receptor II (DNRII).
Main Methods:
- CB NK cells were modified using retroviral transduction to express a dominant-negative TGF-β receptor II (DNRII).
- The cytotoxic function of transduced and non-transduced CB NK cells was evaluated in the presence of MB-conditioned media.
- Expression of CCR2 and TGF-β levels were assessed in modified and unmodified NK cells.
Main Results:
- Non-transduced CB NK cells showed reduced cytotoxicity in TGF-β-rich MB media, while DNRII-transduced NK cells maintained their cytotoxic function.
- Transduced NK cells exhibited preserved CCR2 expression and acted as a cytokine sink, significantly reducing TGF-β levels compared to non-transduced cells.
- DNRII modification prevented the suppressive effects of MB tumor microenvironment on NK cell function.
Conclusions:
- CB NK cells engineered with a TGF-β DNRII demonstrate enhanced function in TGF-β-rich medulloblastoma environments.
- These modified NK cells offer a potential therapeutic advantage over unmodified cells for medulloblastoma treatment.
- Further research is warranted to explore the clinical application of these engineered NK cells in medulloblastoma patients.
